News & Updates
Showing Hepatology articles
Showing
Show Multimedia Only

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
24 Aug 2022
byRoshini Claire Anthony
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.
24 Aug 2022

HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.
14 Aug 2022






